Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: Mechanisms and therapeutic opportunities

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 4, 2011, Pages 613-620

  Schlossarek, Saskia ^a   Mearini, Giulia ^a   Carrier, Lucie ^a,b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Sorbonne Université   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Cardiomyopathy; Hypertrophy; Mutations; Myosin binding protein C; Sarcomere; Ubiquitin proteasome system

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; MUTANT PROTEIN; MYOSIN BINDING PROTEIN C; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

AUTOPHAGY; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LOW DRUG DOSE; MYOFILAMENT; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SARCOMERE;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; HUMANS; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 79952071913     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.01.014     Document Type: Review

References (110)

1. Yamamoto K., Moos C. The C-proteins of rabbit red, white, and cardiac muscles. J Biol Chem 1983, 258:8395-8401.
2. Weber F.E., Vaughan K.T., Reinach F.C., Fischman D.A. Complete sequence of human fast-type and slow-type muscle myosin-binding-protein C (MyBP-C). Differential expression, conserved domain structure and chromosome assignment. Eur J Biochem 1993, 216:661-669.
3. Gautel M., Zuffardi O., Freiburg A., Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction?. EMBO J 1995, 14:1952-1960.
4. Starr R., Offer G. Polypeptide chains of intermediate molecular weight in myosin preparations. FEBS Lett 1971, 15:40-44.
5. Offer G., Moos C., Starr R. A new protein of the thick filaments of vertebrate skeletal myofibrils. Extractions, purification and characterization. J Mol Biol 1973, 74:653-676.
6. Luther P.K., Bennett P.M., Knupp C., Craig R., Padron R., Harris S.P., et al. Understanding the organisation and role of myosin binding protein C in normal striated muscle by comparison with MyBP-C knockout cardiac muscle. J Mol Biol 2008, 384:60-72.
7. Fougerousse F., Delezoide A.L., Fiszman M.Y., Schwartz K., Beckmann J.S., Carrier L. Cardiac myosin binding protein C gene is specifically expressed in heart during murine and human development. Circ Res 1998, 82:130-133.
8. Gautel M., Furst D.O., Cocco A., Schiaffino S. Isoform transitions of the myosin binding protein C family in developing human and mouse muscles: lack of isoform transcomplementation in cardiac muscle. Circ Res 1998, 82:124-129.
9. Yasuda M., Koshida S., Sato N., Obinata T. Complete primary structure of chicken cardiac C-protein (MyBP-C) and its expression in developing striated muscles. J Mol Cell Cardiol 1995, 27:2275-2286.
10. Mohamed A.S., Dignam J.D., Schlender K.K. Cardiac myosin-binding protein C (MyBP-C): identification of protein kinase A and protein kinase C phosphorylation sites. Arch Biochem Biophys 1998, 358:313-319.
11. Jia W., Shaffer J.F., Harris S.P., Leary J.A. Identification of novel protein kinase A phosphorylation sites in the M-domain of human and murine cardiac myosin binding protein-C using mass spectrometry analysis. J Proteome Res 2010, 9:1843-1853.
12. Gruen M., Gautel M. Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin binding protein-C. J Mol Biol 1999, 286:933-949.
13. Gilbert R., Cohen J.A., Pardo S., Basu A., Fishman D.A. Identification of the A-band localization domain of myosin binding proteins C and H (MyBP-C, MyBP-H) in skeletal muscle. J Cell Sci 1999, 112:69-79.
14. Miyamoto C.A., Fischman D.A., Reinach F.C. The interface between MyBP-C and myosin: site-directed mutagenesis of the CX myosin-binding domain of MyBP-C. J Muscle Res Cell Motil 1999, 20:703-715.
15. Freiburg A., Gautel M.A. Molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. Eur J Biochem 1996, 235:317-323.
16. Squire J.M., Luther P.K., Knupp C. Structural evidence for the interaction of C-protein (MyBP-C) with actin and sequence identification of a possible actin-binding domain. J Mol Biol 2003, 331:713-724.
17. Kulikovskaya I., McClellan G., Flavigny J., Carrier L., Winegrad S. Effect of MyBP-C binding to actin on contractility in heart muscle. J Gen Physiol 2003, 122:761-774.
18. Shaffer J.F., Kensler R.W., Harris S.P. The myosin-binding protein C motif binds to F-actin in a phosphorylation-sensitive manner. J Biol Chem 2009, 284:12318-12327.
19. Rybakova I.N., Greaser M.L., Moss R.L. Myosin binding protein C interaction with actin: characterization and mapping of the binding site. J Biol Chem 2010.
20. Winegrad S. Cardiac myosin binding protein C. Circ Res 1999, 84:1117-1126.
21. Moolman-Smook J., Flashman E., de Lange W., Li Z., Corfield V., Redwood C., et al. Identification of novel interactions between domains of myosin binding protein-C that are modulated by hypertrophic cardiomyopathy missense mutations. Circ Res 2002, 91:704-711.
22. Flashman E., Redwood C., Moolman-Smook J., Watkins H. Cardiac myosin binding protein C: its role in physiology and disease. Circ Res 2004, 94:1279-1289.
23. Koretz J.F. Effects of C-protein on synthetic myosin filament structure. Biophys J 1979, 27:433-446.
24. Gilbert R., Kelly M.G., Mikawa T., Fischman D.A. The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J Cell Sci 1996, 109(Pt 1):101-111.
25. Seiler S.H., Fischman D.A., Leinwand L.A. Modulation of myosin filament organization by C-protein family members. Mol Biol Cell 1996, 7:113-127.
26. Sebillon P., Bonne G., Flavigny J., Venin S., Rouche A., Fiszman M., et al. COOH-terminal truncated human cardiac MyBP-C alters myosin filament organization. C R Acad Sci III 2001, 324:251-260.
27. McClellan G., Kulikovskaya I., Flavigny J., Carrier L., Winegrad S. Effect of cardiac myosin-binding protein C on stability of the thick filament. J Mol Cell Cardiol 2004, 37:823-835.
28. Harris S.P., Bartley C.R., Hacker T.A., McDonald K.S., Douglas P.S., Greaser M.L., et al. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ Res 2002, 90:594-601.
29. Carrier L., Knoell R., Vignier N., Keller D.I., Bausero P., Prudhon B., et al. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc Res 2004, 63:293-304.
30. McConnell B.K., Fatkin D., Semsarian C., Jones K.A., Georgakopoulos D., Maguire C.T., et al. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res 2001, 88:383-389.
31. Witt C.C., Gerull B., Davies M.J., Centner T., Linke W.A., Thierfelder L. Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C. J Biol Chem 2001, 276:5353-5359.
32. Vignier N., Schlossarek S., Fraysse B., Mearini G., Kramer E., Pointu H., et al. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res 2009, 105:239-248.
33. Colson B.A., Bekyarova T., Fitzsimons D.P., Irving T.C., Moss R.L. Radial displacement of myosin cross-bridges in mouse myocardium due to ablation of myosin binding protein-C. J Mol Biol 2007, 367:36-41.
34. Lecarpentier Y., Vignier N., Oliviero P., Guellich A., Carrier L., Coirault C. Cardiac myosin-binding protein C modulates the tuning of the molecular motor in the heart. Biophys J 2008, 95:720-728.
35. Herron T.J., Rostkova E., Kunst G., Chaturvedi R., Gautel M., Kentish J.C. Activation of myocardial contraction by the N-terminal domains of myosin binding protein-C. Circ Res 2006, 98:1290-1298.
36. Stelzer J.E., Dunning S.B., Moss R.L. Ablation of cardiac myosin-binding protein-C accelerates stretch activation in murine skinned myocardium. Circ Res 2006, 98:1212-1218.
37. Sadayappan S., Osinska H., Klevitsky R., Lorenz J.N., Sargent M., Molkentin J.D., et al. Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci USA 2006, 103:16918-16923.
38. Cazorla O., Szilagyi S., Vignier N., Salazar G., Kramer E., Vassort G., et al. Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc Res 2006, 69:370-380.
39. Pohlmann L., Kroger I., Vignier N., Schlossarek S., Kramer E., Coirault C., et al. Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res 2007, 101:928-938.
40. McConnell B.K., Jones K.A., Fatkin D., Arroyo L.H., Lee R.T., Aristizabal O., et al. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 1999, 104:1235-1244.
41. Eijssen L.M., van den Bosch B.J., Vignier N., Lindsey P.J., van den Burg C.M., Carrier L., et al. Altered myocardial gene expression reveals possible maladaptive processes in heterozygous and homozygous cardiac myosin-binding protein C knockout mice. Genomics 2008, 91:52-60.
42. Barefield D., Sadayappan S. Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 2010, 48:866-875.
43. Hartzell H.C., Glass D.B. Phosphorylation of purified cardiac muscle C-protein by purified cAMP-dependent and endogenous Ca2+-calmodulin-dependent protein kinases. J Biol Chem 1984, 259:15587-15596.
44. Schlender K.K., Bean L.J. Phosphorylation of chicken cardiac C-protein by calcium/calmodulin-dependent protein kinase II. J Biol Chem 1991, 266:2811-2817.
45. Pyle W.G., Chen Y., Hofmann P.A. Cardioprotection through a PKC-dependent decrease in myofilament ATPase. Am J Physiol Heart Circ Physiol 2003, 285:H1220-H1228.
46. Xiao L., Zhao Q., Du Y., Yuan C., Solaro R.J., Buttrick P.M. PKCepsilon increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in vitro and in vivo. Biochemistry 2007, 46:7054-7061.
47. Bardswell S.C., Cuello F., Rowland A.J., Sadayappan S., Robbins J., Gautel M., et al. Distinct sarcomeric substrates are responsible for protein kinase D-mediated regulation of cardiac myofilament Ca2+ sensitivity and cross-bridge cycling. J Biol Chem 2010, 285:5674-5682.
48. Cuello F., Bardswell S.C., Haworth R.S., Ehler E., Sadayappan S., Kentish J.C., et al. A novel role for p90 ribosomal S6 kinase in the regulation of cardiac myofilament phosphorylation. J Biol Chem 2010.
49. Patel J.R., Fitzsimons D.P., Buck S.H., Muthuchamy M., Wieczorek D.F., Moss R.L. PKA accelerates rate of force development in murine skinned myocardium expressing alpha- or beta-tropomyosin. Am J Physiol Heart Circ Physiol 2001, 280:H2732-H2739.
50. Layland J., Solaro R.J., Shah A.M. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 2005, 66:12-21.
51. Colson B.A., Bekyarova T., Locher M.R., Fitzsimons D.P., Irving T.C., Moss R.L. Protein kinase A-mediated phosphorylation of cMyBP-C increases proximity of myosin heads to actin in resting myocardium. Circ Res 2008, 103:244-251.
52. Chen P.P., Patel J.R., Rybakova I.N., Walker J.W., Moss R.L. Protein kinase A-induced myofilament desensitization to Ca2+ as a result of phosphorylation of cardiac myosin-binding protein C. J Gen Physiol 2010, 136:615-627.
53. Sadayappan S., Gulick J., Osinska H., Martin L.A., Hahn H.S., Dorn G.W., et al. Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res 2005, 97:1156-1163.
54. Jacques A.M., Copeland O., Messer A.E., Gallon C.E., King K., McKenna W.J., et al. Myosin binding protein C phosphorylation in normal, hypertrophic and failing human heart muscle. J Mol Cell Cardiol 2008, 45:209-216.
55. van Dijk S.J., Dooijes D., dos Remedios C., Michels M., Lamers J.M., Winegrad S., et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009, 119:1473-1483.
56. Copeland O., Sadayappan S., Messer A.E., Steinen G.J., van der Velden J., Marston S.B. Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. J Mol Cell Cardiol 2010, 49:1003-1011.
57. El-Armouche A., Pohlmann L., Schlossarek S., Starbatty J., Yeh Y.H., Nattel S., et al. Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol 2007, 43:223-229.
58. El-Armouche A., Boknik P., Eschenhagen T., Carrier L., Knaut M., Ravens U., et al. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation 2006, 114:670-680.
59. Belus A., Piroddi N., Ferrantini C., Tesi C., Cazorla O., Toniolo L., et al. Effects of chronic atrial fibrillation on active and passive force generation in human atrial myofibrils. Circ Res 2010, 107:144-152.
60. Boontje N.M., Merkus D., Zaremba R., Versteilen A., de Waard M.C., Mearini G., et al. Enhanced myofilament responsiveness upon beta-adrenergic stimulation in post-infarct remodeled myocardium. J Mol Cell Cardiol 2010.
61. Jacquet S., Yin X., Sicard P., Clark J., Kanaganayagam G.S., Mayr M., et al. Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol Cell Proteomics 2009, 8:2687-2699.
62. Richardson P., McKenna W., Bristow M., Maish B., Mautner B., O'Connell J., et al. Report of the 1995 World Health Organisation/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996, 93:841-842.
63. Elliott P., Andersson B., Arbustini E., Bilinska Z., Cecchi F., Charron P., et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008, 29:270-276.
64. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287:1308-1320.
65. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 1995, 92:785-789.
66. Charron P., Carrier L., Dubourg O., Tesson F., Desnos M., Richard P., et al. Penetrance of familial hypertrophic cardiomyopathy. Genet Couns 1997, 8:107-114.
67. Richard P., Villard E., Charron P., Isnard R. The genetic bases of cardiomyopathies. J Am Coll Cardiol 2006, 48:A79-A89.
68. Alcalai R., Seidman J.G., Seidman C.E. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008, 19:104-110.
69. Carrier L., Schlossarek S., Willis M.S., Eschenhagen T. The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res 2010, 85:330-338.
70. Marian A.J. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 2010, 40:360-369.
71. Wang H., Li Z., Wang J., Sun K., Cui Q., Song L., et al. Mutations in NEXN, a Z-disc gene, are associated with hypertrophic cardiomyopathy. Am J Hum Genet 2010, 87:687-693.
72. Chiu C., Bagnall R.D., Ingles J., Yeates L., Kennerson M., Donald J.A., et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. J Am Coll Cardiol 2010, 55:1127-1135.
73. Chen S.N., Rodriguez G., Czernuszewicz G., Jin U.H., Jin J.P., Marian A.J. TRIM63, encoding MuRF1, is a novel gene for familial hypertrophic cardiomyopathy. Circ 2010, 122(Suppl):A21194.
74. Richard P., Charron P., Carrier L., Ledeuil C., Cheav T., Pichereau C., et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations and implications for molecular diagnosis strategy. Circulation 2003, 107:2227-2232.
75. Ingles J., Doolan A., Chiu C., Seidman J., Seidman C., Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 2005, 42:e59.
76. Millat G., Bouvagnet P., Chevalier P., Dauphin C., Jouk P.S., Da Costa A., et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet 2010, 53:261-267.
77. Charron P., Dubourg O., Desnos M., Bennaceur M., Carrier L., Camproux A.C., et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998, 97:2230-2236.
78. Niimura H., Bachinski L.L., Sangwatanaroj S., Watkins H., Chudley A.E., McKenna W., et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998, 338:1248-1257.
79. Yu B., French J.A., Carrier L., Jeremy R.W., McTaggart D.R., Nicholson M.R., et al. Molecular pathology of familial hypertrophic cardiomyopathy caused by mutations in the cardiac myosin binding protein C gene. J Med Genet 1998, 35:205-210.
80. Ehlermann P., Weichenhan D., Zehelein J., Steen H., Pribe R., Zeller R., et al. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med Genet 2008, 9:95.
81. Richard P., Isnard R., Carrier L., Dubourg O., Donatien Y., Mathieu B., et al. Double heterozygosity for mutations in the beta myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J Med Genet 1999, 36:542-545.
82. Keller D.I., Coirault C., Rau T., Cheav T., Weyand M., Amann K., et al. Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol 2004, 36:355-362.
83. Charron P., Dubourg O., Desnos M., Bouhour J.B., Isnard R., Hagege A., et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. Eur Heart J 1998, 19:1377-1382.
84. Tesson F., Dufour C., Moolman J.C., Carrier L., Al-Mahdawi S., Brink P., et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 1997, 29:831-838.
85. Osterop A.P., Kofflard M.J., Sandkuijl L.A., ten Cate F.J., Krams R., Schalekamp M.A., et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 1998, 32:825-830.
86. Deinum J., van Gool J.M., Kofflard M.J., ten Cate F.J., Danser A.H. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 2001, 38:1278-1281.
87. Friedrich F.W., Bausero P., Sun Y., Treszl A., Kramer E., Juhr D., et al. A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. Eur Heart J 2009, 30:1648-1655.
88. Carrier L., Bonne G., Bährend E., Yu B., Richard P., Niel F., et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res 1997, 80:427-434.
89. Dhandapany P.S., Sadayappan S., Xue Y., Powell G.T., Rani D.S., Nallari P., et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet 2009, 41:187-191.
90. Rottbauer W., Gautel M., Zehelein J., Labeit S., Franz W.M., Fischer C., et al. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization of cardiac transcript and protein. J Clin Invest 1997, 100:475-482.
91. Moolman J.A., Reith S., Uhl K., Bailey S., Gautel M., Jeschke B., et al. A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation 2000, 101:1396-1402.
92. Marston S., Copeland O., Jacques A., Livesey K., Tsang V., McKenna W.J., et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 2009, 105:219-222.
93. Flavigny J., Souchet M., Sébillon P., Berrebi-Bertrand I., Hainque B., Mallet A., et al. COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes. J Mol Biol 1999, 294:443-456.
94. Sarikas A., Carrier L., Schenke C., Doll D., Flavigny J., Lindenberg K.S., et al. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res 2005, 66:33-44.
95. Bahrudin U., Morisaki H., Morisaki T., Ninomiya H., Higaki K., Nanba E., et al. Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. J Mol Biol 2008, 384:896-907.
96. Yang Q., Sanbe A., Osinska H., Hewett T.E., Klevitsky R., Robbins J. In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ Res 1999, 85:841-847.
97. Garneau N.L., Wilusz J., Wilusz C.J. The highways and byways of mRNA decay. Nat Rev Mol Cell Biol 2007, 8:113-126.
98. Linde L., Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 2008, 24:552-563.
99. Geiger S.K., Bar H., Ehlermann P., Walde S., Rutschow D., Zeller R., et al. Incomplete nonsense-mediated decay of mutant lamin A/C mRNA provokes dilated cardiomyopathy and ventricular tachycardia. J Mol Med 2008, 86:281-289.
100. Gong Q., Zhang L., Vincent G.M., Horne B.D., Zhou Z. Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome. Circulation 2007, 116:17-24.
101. Mearini G., Schlossarek S., Willis M.S., Carrier L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 2008, 1782:749-763.
102. Mearini G., Gedicke C., Schlossarek S., Witt C.C., Kramer E., Cao P., et al. Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc Res 2010, 85:357-366.
103. Flavigny J., Robert P., Camelin J.C., Schwartz K., Carrier L., Berrebi-Bertrand I. Biomolecular interactions between human recombinant beta-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy. Cardiovasc Res 2003, 60:388-396.
104. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
105. De Meyer G.R., Martinet W. Autophagy in the cardiovascular system. Biochim Biophys Acta 2009, 1793:1485-1495.
106. Carrier L. Too much of a good thing is bad: proteasome inhibition induces stressed hearts to fail. Cardiovasc Res 2010, 88:389-390.
107. Le Roy F., Charton K., Lorson C.L., Richard I. RNA-targeting approaches for neuromuscular diseases. Trends Mol Med 2009, 15:580-591.
108. Gedicke C., Behrens-Gawlik V., Dreyfus P.A., Eschenhagen T., Carrier L. Specific skipping of exons using antisense oligoribonucleotides results in a novel molecule in cMyBP-C knock-in mouse myocytes. Circ 2010, 122(Suppl):A19079.
109. Hansen A., Eder A., Bonstrup M., Flato M., Mewe M., Schaaf S., et al. Development of a drug screening platform based on engineered heart tissue. Circ Res 2010, 107:35-44.
110. Arimura T., Matsumoto Y., Okazaki O., Hayashi T., Takahashi M., Inagaki N., et al. Structural analysis of obscurin gene in hypertrophic cardiomyopathy. Biochem Biophys Res Commun 2007, 362:281-287.